SHARONBIO

The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to recent news item captioned " USFDA approves Sharon Bio's Taloja API plant." In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.

Sharon Bio-Medicine Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from September 20, 2016 to September 27, 2016 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on September 27, 2016.

Sharon Bio-Medicine Limited has informed the Exchange regarding the Outcome of Board Meeting of the Company held on August 11, 2016.

Sharon Bio-Medicine Limited has submitted to the Exchange the standalone financial results along with the Limited Review Report for the period ended 30-Jun-2016.

Sharon Bio-Medicine Limited has informed the Exchange that as decided in the Meeting of the Board of Directors of the Company held on June 21, 2016, for which intimation was already given to you, the Board of Directors: 1) Discussed the current financial position of the Company and decided to introduce more profitable products increase capacity utilization and get the business to move in the regulated markets specifically the United States of America.

:The Exchange had sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 12-Jan-2016 regarding the Board of Directors at their meeting held on January 12, 2016 have discussed the below:1. Closure of the subsidiary company M/s Yusur International FZE.On basis of above, the reply from the Company vide letter dated June 20, 2016 is attached.

Sharon Bio-Medicine Limited has informed the Exchange that Mr. Viral Dilip Vora, being Company Secretary in whole time in employment has resigned as a Company Secretary as well as Compliance Officer of the Company w.e.f May 31, 2016.

Sharon Bio-Medicine Limited has submitted to the Exchange the standalone & consolidated financial results along with the Auditors Report for the period ended .

Sharon Bio-Medicine Limited has informed the Exchange that the trading window for dealing in the securities of the Company will be closed for the purpose of declaration of financial results of the Company from May 20, 2016 to June 1, 2016.

Lalit Misra has submitted to the Exchange vide letter dated April 11, 2016 a copy of disclosure under Regulation 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sharon Bio-Medicine Limited has submitted to the Exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended December 31, 2015.

Sharon Bio-Medicine Limited has informed the Exchange that the Trading Window will be closed for the corporate invent February 10, 2016 To February 16, 2016. The trading window will be open on February 17, 2016

SHARONBIO: The Exchange has sought clarification from the Company with respect to announcement dated January 12, 2016, that the Board of Directors at their meeting held on January 12, 2016 have discussed the Closure of the subsidiary company M/s Yusur International FZE. On basis of above Company is required to clarify following -1. The amount and percentage of the turnover or revenue or income and net worth contributed by such entity during the last financial year; 2. Impact on the Company due to Closure.The response of the Company is awaited.

Sharon Bio-Medicine Limited has informed the Exchange that the Board of Directors at their meeting held on January 12, 2016 have discussed the below:1. Closure of the subsidiary company M/s Yusur International FZE.2. Acceptance of Resignation of Mr. Mohan Kala and Mr. Madhav Sapre from the office of Director w.e.f December 31, 2015.

Sharon Bio-Medicine Limited has informed the Exchange that the Company closes its financial year as on June 30, every year and to align with the provisions Section 2 (41) of Companies Act, 2013, the Company want to close the financial year on the coming March 31,2016 by preparing the Financial Statements for a period of 9 months commencing from July 01, 2015 to March 31, 2016."

Sharon Bio-Medicine Limited has informed the Exchange regarding Voting Result of Annual General Meeting held on December 31, 2015.

Sharon Bio-Medicine Limited has submitted to the Exchange a copy of the Proceedings of the Annual General Meeting of the Company held on December 31, 2015.

Sharon Bio-Medicine Limited has informed the Exchange vide letter dated December 17, 2015 regarding "Intimation for clearing National Good Laboratory Practice (GLP) Compliance Monitoring Authority (NGCMA) surveillance inspection".

Sharon Bio-Medicine Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from December 25, 2015 to December 31, 2015 (both days inclusive) for the purpose of Annual General Meeting of the Company is scheduled to be held on December 31, 2015.

Sharon Bio-Medicine Limited has informed the Exchange regarding "Sharon Bio Medicine Ltd. U.S. FDA News".

Sharon Bio-Medicine Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Sep-2015.

Sharon Bio-Medicine Limited has informed the Exchange that in terms of Code of conduct adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will be closed from November 6, 2015 to November 16, 2015. The trading window will open on November 17, 2015.

Sharon Bio-Medicine Limited has informed the Exchange that M/s. India Factoring And Finance Solutions Pvt. Ltd. from whom Company have taken unsecured loan had filed the case under U/S 433 and 434 of the Companies Act, 1956. The Company has challenged the case in the Bombay High Court and asked the Honourable Court to dismiss the Petition as the same is devoid of any merit.

Sharon Bio-Medicine Limited has submitted to the exchange the standalone financial results along with the Auditors Report for the period ended 30-Jun-2015.

Sharon Bio-Medicine Limited has informed the Exchange that in the last week one of the Company's Formulation Plant at Dehradun in Uttarakhand has been Inspected and Audited by USFDA officials. This is Company's second plant which has been Inspected and Audited by USFDA officials in the last 2 months. First plant at Taloja near Navi Mumbai was Inspected and Audited in the first week of July 2015 and was intimated to the Exchange on July 9, 2015.Company hope to add Company's Active Pharma Ingredient and Formulation sales to United State Of America (USA) apart from many European and other countri

Sharon Bio-Medicine Limited has informed the Exchange that in terms of Code of conduct adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will be closed from August 27, 2015 to September 1, 2015. The trading window will open on September 2, 2015.

Significant price movement has been observed in Sharon Bio-Medicine Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sharon Bio-Medicine Limited has informed the Exchange that "From 29th June 2015 at one of the manufacturing plant at MIDC, Taloja near Navi Mumbai the US FDA Audit is concluded and we are understanding the outcome of US FDA Inspection. The US FDA Audit was completed on 7th July 2015 night."

Sharon Bio-Medicine Limited has informed the Exchange that one of the Unit Located at L-6, MIDC, Taloja. Dist. Raigad, Maharashtra has been inspected and audited by USFDA inspectors for 7 days starting from June 29, 2015. The Audit was Completed on July 7, 2015. (Revised)

Sharon Bio-Medicine Limited has informed the Exchange that one of the Company unit Located at L-6, MIDC, Taloja Dist. Raigad, Maharashtra has been inspected and audited by USFDA inspectors for 7 days starting from July 06, 2015. The Audit was Completed on July 14, 2015.

Bagulvani General Trading Pvt. Ltd and Ramco Properties Pvt. Ltd and Venus Global Management & Consultancy Services Private Limited has submitted to the Exchange vide letter dated June 11, 2015 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sharon Bio-Medicine Limited has informed the Exchange regarding outcome of meeting of the Board of Directors of the Company held on June 10, 2015.

Sharon Bio-Medicine Limited has informed the Exchange that In terms of Code of conduct adopted by the Company under SEBI (Prohibition of Insider Trading) Regulatiors, 2015. All Directors/ Officers / Designated employees of the Company are advised not to deal in shares of the Company during the trading window is closed from June 8, 2015 to June 12, 2015 on event of allotment of Equity shares in exchange of warrants. The trading window will open on June 15, 2015.

Sharon Bio-Medicine Limited has informed the Exchange that the code of conduct adopted by the Board of Directors in their meeting held on May 27, 2015 under SEBI {(Prohibition of insider Trading) Reg, 2015.

Sharon Bio-Medicine Limited has submitted to the exchange the standalone financial results for the period ended 31-Mar-2015.

Sharon Bio-Medicine Limited has informed the Exchange that the trading window will be closed from May 5, 2015 to May 15, 2015 (both days inclusive).

Revon Consultancy & Management Services Private Limited, Ramco Properties Pvt. Ltd., Bagulvani General Trading Pvt. Ltd. & Venus Global Management & Consultancy Services Pvt. Ltd., has submitted to the Exchange vide letter dated April 18, 2015 a copy of revised disclosure under Regulation 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shambhu Prasad Misra has submitted to the Exchange vide letter dated April 10, 2015 a copy of disclosure under Regulation 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Asha Kala has submitted to the Exchange vide letter dated April 08, 2015 a copy of disclosure under Regulation 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Basanti Misra has submitted to the Exchange vide letter dated April 08, 2015 a copy of disclosure under Regulation 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Lalit Misra has submitted to the Exchange vide letter dated April 08, 2015 a copy of disclosure under Regulation 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Savita Gowda has submitted to the Exchange vide letter dated April 08, 2015 a copy of disclosure under Regulation 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Preeti Misra has submitted to the Exchange vide letter dated April 08, 2015 a copy of disclosure under Regulation 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Mohan Kala has submitted to the Exchange vide letter dated April 08, 2015 a copy of disclosure under Regulation 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Venus Global Management & Consultancy Services Pvt Ltd has submitted to the Exchange vide letter dated April 08, 2015 a copy of disclosure under Regulation 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Bagulvani General Trading Private Limited has submitted to the Exchange vide letter dated April 08, 2015 a copy of disclosure under Regulation 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Ramco Properties Private Limited has submitted to the Exchange vide letter dated April 08, 2015 a copy of disclosure under Regulation 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Revon Consultancy & Management Services Pvt. Ltd. has submitted to the Exchange vide letter dated April 08, 2015 a copy of disclosure under Regulation 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sharon Bio-Medicine Limited has informed the Exchange that the proposal for restructuring of the debts of the Company has been accepted by all its bankers, accordingly the Master Restructuring Agreement has been executed by all the bankers. The Board of Directors have already intimated regarding the restructuring of debts to the concerned stock exchanges on March 16, 2015.

Sharon Bio-Medicine Limited has informed the Exchange regarding the Outcome of Board Meeting of the Company held on March 30, 2015.

Sharon Bio-Medicine Limited has informed the Exchange that Mr. Vijay Kirpalani and Mr. Asif Rangwala has resigned as the Directors of the Company w.e.f. March 24, 2015.